GlobeNewswire: Nemucore Medical Innovations, Inc. Contains the last 10 of 9 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:13:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/05/23/842388/0/en/Nemucore-Study-Published-in-Molecular-Pharmaceutics-Furthers-Understanding-of-NMI-350-and-Theranostics-for-Ovarian-Cancer.html?f=22&fvtc=4&fvtv=27868Nemucore Study Published in Molecular Pharmaceutics Furthers Understanding of NMI-350 and Theranostics for Ovarian Cancer2016-05-23T12:05:00Z<![CDATA[New preclinical data supports the development of the targeted theranostic New preclinical data supports the development of the targeted theranostic]]>https://www.globenewswire.com/news-release/2016/05/16/840248/0/en/Nemucore-Medical-Innovations-Announces-Appointment-of-Nicholas-De-Monico-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations Announces Appointment of Nicholas De Monico to its Board of Directors2016-05-16T12:05:00Z<![CDATA[Nicholas De Monico brings over 35 years of financial leadership Nicholas De Monico brings over 35 years of financial leadership]]>https://www.globenewswire.com/news-release/2016/05/12/839441/0/en/Nemucore-Medical-Innovations-Announces-NMI-350-ACOG-Poster-Presentation.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations Announces NMI-350 ACOG Poster Presentation2016-05-12T12:05:00Z<![CDATA[WORCESTER, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced its poster presentation at American Congress of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, May 16, 2016, in Washington DC at the Washington Convention Center. Nemucore will present a poster on its targeted platinum therapy NMI-350.]]>https://www.globenewswire.com/news-release/2016/05/11/838875/0/en/Nemucore-Medical-Innovations-Announces-NMI-500-ACOG-Poster-Presentation.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations Announces NMI-500 ACOG Poster Presentation2016-05-11T12:05:00Z<![CDATA[WORCESTER, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced its poster presentation at American Congress of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, May 16, 2016, in Washington DC at the Washington Convention Center. Nemucore will present a poster on its targeted therapy NMI-500.]]>https://www.globenewswire.com/news-release/2016/04/05/825908/0/en/Nemucore-Medical-Innovations-to-Present-at-Needham-Company-s-15th-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations to Present at Needham & Company’s 15th Annual Healthcare Conference2016-04-05T12:05:00Z<![CDATA[WORCESTER, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, announced today that Timothy P. Coleman, President and Chief Executive Officer, will present a corporate overview and update at the Needham & Company’s 15th Annual Healthcare Conference on April 12-13, 2016 in New York City. The Nemucore presentation will take place at 09:20 AM on Wednesday, April 13, 2016. ]]>https://www.globenewswire.com/news-release/2015/12/14/795191/0/en/Nemucore-Medical-Innovations-Announces-Licensing-Agreement-With-Pfenex-Inc-Enabling-Manufacture-of-Anti-Cancer-Therapeutic-NMI-8000-the-Biologically-Active-Form-of-Mullerian-Inhibi.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations Announces Licensing Agreement With Pfenex Inc. Enabling Manufacture of Anti-Cancer Therapeutic NMI-8000, the Biologically Active Form of Mullerian Inhibitory Substance (MIS)2015-12-14T13:05:00Z<![CDATA[Agreement Grants Nemucore Rights to Expression Technology for the Production of Its Novel Therapeutic Targeting Female Reproductive Cancers Agreement Grants Nemucore Rights to Expression Technology for the Production of Its Novel Therapeutic Targeting Female Reproductive Cancers]]>https://www.globenewswire.com/news-release/2015/12/09/794110/0/en/Nemucore-Medical-Innovations-Announces-Appointment-of-Dr-Michael-V-Seiden-to-Its-Board-of-Directors-and-Clinical-Advisory-Board.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations Announces Appointment of Dr. Michael V. Seiden to Its Board of Directors and Clinical Advisory Board2015-12-09T13:05:00Z<![CDATA[Dr. Seiden Brings Unparalleled Clinical and Industry Expertise in the Field of Oncology Dr. Seiden Brings Unparalleled Clinical and Industry Expertise in the Field of Oncology]]>https://www.globenewswire.com/news-release/2015/12/07/793425/0/en/Nemucore-Medical-Innovations-Options-Clinical-Stage-Aurora-Kinase-Inhibitor-GSK1070916-From-Cancer-Research-Technology-CRT.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations Options Clinical-Stage Aurora Kinase Inhibitor GSK1070916 From Cancer Research Technology (CRT)2015-12-07T13:10:00Z<![CDATA[Phase 2 Candidate Targets a Broad Range of Multi-Drug Resistant Cancers Including Ovarian, Breast, Lung and Hematological Indications Phase 2 Candidate Targets a Broad Range of Multi-Drug Resistant Cancers Including Ovarian, Breast, Lung and Hematological Indications]]>https://www.globenewswire.com/news-release/2015/12/07/793419/0/en/Nemucore-Medical-Innovations-Completes-Series-A-Financing.html?f=22&fvtc=4&fvtv=27868Nemucore Medical Innovations Completes Series A Financing2015-12-07T13:05:00Z<![CDATA[Proceeds to Support Clinical-Stage Programs and Expansion of Women’s Oncology Therapeutic Pipeline Proceeds to Support Clinical-Stage Programs and Expansion of Women’s Oncology Therapeutic Pipeline]]>